Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isaac Kendell

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
ACS Nano|August 16, 2024
Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating TherapyM Tommy Gambles, Shannuo Li, Isaac Kendell, et al.
Communications Biology|July 13, 2026
Computer-guided dosing of multi-specific T-cell engagersIsaac Kendell, Richard McShinsky, Katarzyna Modzelewska, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|May 2, 2025
Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacyM Tommy Gambles, Isaac Kendell, Jiahui Li, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
ACS Nano|August 16, 2024
Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating TherapyM Tommy Gambles, Shannuo Li, Isaac Kendell, et al.
Communications Biology|July 13, 2026
Computer-guided dosing of multi-specific T-cell engagersIsaac Kendell, Richard McShinsky, Katarzyna Modzelewska, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|May 2, 2025
Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacyM Tommy Gambles, Isaac Kendell, Jiahui Li, et al.
Pageof 1